135 related articles for article (PubMed ID: 7743513)
1. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.
Mirski SE; Cole SP
Cancer Res; 1995 May; 55(10):2129-34. PubMed ID: 7743513
[TBL] [Abstract][Full Text] [Related]
2. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Yu Q; Mirski SE; Sparks KE; Cole SP
Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
[TBL] [Abstract][Full Text] [Related]
3. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
4. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
6. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
Harker WG; Slade DL; Parr RL; Holguin MH
Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
[TBL] [Abstract][Full Text] [Related]
8. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
McPherson JP; Brown GA; Goldenberg GJ
Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
[TBL] [Abstract][Full Text] [Related]
11. Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha.
de Lucio B; Manuel V; Barrera-RodrÃguez R
Cancer Sci; 2005 Nov; 96(11):774-83. PubMed ID: 16271071
[TBL] [Abstract][Full Text] [Related]
12. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
Mo YY; Beck WT
Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
[TBL] [Abstract][Full Text] [Related]
14. Bipartite nuclear localization signals in the C terminus of human topoisomerase II alpha.
Mirski SE; Gerlach JH; Cummings HJ; Zirngibl R; Greer PA; Cole SP
Exp Cell Res; 1997 Dec; 237(2):452-5. PubMed ID: 9434641
[TBL] [Abstract][Full Text] [Related]
15. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
[TBL] [Abstract][Full Text] [Related]
16. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
Hashimoto S; Danks MK; Chatterjee S; Beck WT; Berger NA
Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
[TBL] [Abstract][Full Text] [Related]
17. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
18. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
20. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]